A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

Wu, Qian; Xiong, Yiting; Zhang, Shujuan; Chen, Xinling; Yi, Fengming; Wei, Yiping

doi:10.3389/fonc.2019.01460

Cited by 11 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The updated search yielded six records. [5][6][7][8][9][10] A review of these results revealed no new evidence that would warrant substantive modification of the ASTRO Radiation Therapy for Small-Cell Lung Cancer guideline practice recommendations.…”

Section: Methods and Results Of The Asco Updated Literature Reviewmentioning

confidence: 99%

Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline

Daly

Ismaila

Decker

et al. 2021

JCO

View full text Add to dashboard Cite

PURPOSE The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy (RT) for small-cell lung cancer (SCLC). Because of the relevance of this topic to ASCO membership, ASCO reviewed the guideline, applying a set of procedures and policies used to critically examine guidelines developed by other organizations. METHODS The ASTRO guideline on RT for SCLC was reviewed for developmental rigor by methodologists. Then, an ASCO Expert Panel reviewed the content and the recommendations. RESULTS The ASCO Expert Panel determined that the recommendations from ASTRO guideline on RT for SCLC, published in June 2020, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed ASTRO guideline on RT for SCLC with a few discussion points. RECOMMENDATIONS Recommendations addressed thoracic radiotherapy for limited-stage SCLC, role of stereotactic body radiotherapy in stage I or II node-negative SCLC, prophylactic cranial radiotherapy, and thoracic consolidation for extensive-stage SCLC. Additional information is available at www.asco.org/thoracic-cancer-guidelines .

show abstract

Section: Methods and Results Of The Asco Updated Literature Reviewmentioning

confidence: 99%

Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline

Daly

Ismaila

Decker

et al. 2021

JCO

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis based on the literature confirmed that BD is better than OD in terms of outcomes (13). A survey of European practice showed that BD radiotherapy delivery increased after the publication of the CONVERT trial (32% prior to and 42% after the publication).…”

Section: Dose and Fractionationmentioning

confidence: 99%

“…Concurrent thoracic CTRT is the mainstay of treatment for patients with LS (stage I−III: T1−4, N0−3 M0 tumours) with a good performance status (PS) 0−1. Gold-standard management is early (starting with the first or second cycle of chemotherapy) (11) accelerated hyperfractionated twicedaily (BD) CTRT (4 cycles of cisplatin etoposide) (12)(13)(14) with modern radiation techniques [intensity modulated radiotherapy (IMRT); data from non-small cell lung cancer (NSCLC) setting] (15). Post-chemotherapy tumour volume and involved-field radiotherapy should be applied (7).…”

Section: Limited Stage (T1−4 N0−3 M0)mentioning

confidence: 99%

Thoracic radiotherapy in small cell lung cancer—a narrative review

Lévy¹,

Botticella²,

Péchoux³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC) represents 10-15% of all lung cancers and has a poor prognosis.Thoracic radiotherapy plays a central role in current SCLC management. Concurrent chemoradiotherapy (CTRT) is the standard of care for localised disease (stage I−III, limited-stage, LS). Definitive thoracic radiotherapy may be offered in metastatic patients (stage IV, extensive stage, ES-SCLC) after chemotherapy.For LS-SCLC, the gold standard is early accelerated hyperfractionated twice-daily CTRT (4 cycles of cisplatin etoposide, starting with the first or second chemotherapy cycle). Modern radiation techniques should be used with involved-field radiotherapy based on baseline CT and PET/CT scans. In ES-SCLC, thoracic radiotherapy should be discussed in cases of initial bulky mediastinal disease/residual thoracic disease not progressing after induction chemotherapy. This strategy was however not assessed in recent trials establishing chemo-immunotherapy as the standard first line treatment in ES-SCLC. Future developments include technical radiotherapy advances and the incorporation of new drugs. Thoracic irradiation is delivered more precisely given technical developments (IMRT, image-guided radiotherapy, stereotactic radiotherapy), reducing the risks of severe adverse events. Stereotactic ablative radiotherapy may be discussed in rare early stage (T1 to 2, N0) inoperable patients. A number of current clinical trials are investigating immunoradiotherapy. In this review, we highlight the current role of thoracic radiotherapy and describe ongoing research in the integration of biological surrogate markers, advanced radiotherapy technologies and novel drugs in SCLC patients.

show abstract

“…A recent MTA[ 77 ] compared the efficacy and toxicity of twice-daily to once-daily CRT, finding significantly better overall survival with the twice-daily regimen and no differences in toxicity.…”

Section: Clinical Treatment Indications For Each Sclc Stagementioning

confidence: 99%

GOECP/SEOR radiotherapy guidelines for small-cell lung cancer

Couñago

Pinta

Gonzalo

et al. 2021

WJCO

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) accounts for approximately 20% of all lung cancers. The main treatment is chemotherapy (Ch). However, the addition of radiotherapy significantly improves overall survival (OS) in patients with non-metastatic SCLC and in those with metastatic SCLC who respond to Ch. Prophylactic cranial irradiation reduces the risk of brain metastases and improves OS in both metastatic and non-metastatic patients. The 5-year OS rate in patients with limited-stage disease (non-metastatic) is slightly higher than 30%, but less than 5% in patients with extensive-stage disease (metastatic). The present clinical guidelines were developed by Spanish radiation oncologists on behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Society of Radiation Oncology to provide a current review of the diagnosis, planning, and treatment of SCLC. These guidelines emphasise treatment fields, radiation techniques, fractionation, concomitant treatment, and the optimal timing of Ch and radiotherapy. Finally, we discuss the main indications for reirradiation in local recurrence.

show abstract

A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials

Cited by 11 publications

References 33 publications

Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline

Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline

Thoracic radiotherapy in small cell lung cancer—a narrative review

GOECP/SEOR radiotherapy guidelines for small-cell lung cancer

Contact Info

Product

Resources

About